221 related articles for article (PubMed ID: 34059720)
21. Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor.
So A; Sakaguchi K; Okada Y; Morita Y; Yamada T; Miura H; Otowa-Suematsu N; Nakamura T; Komada H; Hirota Y; Tamori Y; Ogawa W
Endocr J; 2020 May; 67(5):501-507. PubMed ID: 32023587
[TBL] [Abstract][Full Text] [Related]
22. Anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective glycemic control from single center.
Calapkulu M; Cander S; Gul OO; Ersoy C
Diabetes Metab Syndr; 2019; 13(1):284-288. PubMed ID: 30641713
[TBL] [Abstract][Full Text] [Related]
23. Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT).
Viswanathan V; Singh KP
Diabetes Technol Ther; 2019 Aug; 21(8):415-422. PubMed ID: 31339784
[No Abstract] [Full Text] [Related]
24. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
25. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
Rajeev SP; Sprung VS; Roberts C; Harrold JA; Halford JC; Stancak A; Boyland EJ; Kemp GJ; Cuthbertson DJ; Wilding JP
BMJ Open; 2017 Jan; 7(1):e013539. PubMed ID: 28132008
[TBL] [Abstract][Full Text] [Related]
26. Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Aso Y; Sagara M; Niitani T; Kato K; Iijima T; Tomaru T; Jojima T; Usui I
J Investig Med; 2021 Oct; 69(7):1324-1329. PubMed ID: 34016738
[TBL] [Abstract][Full Text] [Related]
27. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
[TBL] [Abstract][Full Text] [Related]
28. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
[TBL] [Abstract][Full Text] [Related]
29. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
Leiter LA; Cefalu WT; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
J Am Geriatr Soc; 2014 Jul; 62(7):1252-62. PubMed ID: 24890683
[TBL] [Abstract][Full Text] [Related]
30. Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.
Ito S; Hosaka T; Yano W; Itou T; Yasumura M; Shimizu Y; Kobayashi H; Nakagawa T; Inoue K; Tanabe S; Kondo T; Ishida H
Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29520981
[TBL] [Abstract][Full Text] [Related]
31. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
33. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
34. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.
Bays HE; Sartipy P; Xu J; Sjöström CD; Underberg JA
J Clin Lipidol; 2017; 11(2):450-458.e1. PubMed ID: 28502502
[TBL] [Abstract][Full Text] [Related]
35. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
[TBL] [Abstract][Full Text] [Related]
36. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
Schork A; Saynisch J; Vosseler A; Jaghutriz BA; Heyne N; Peter A; Häring HU; Stefan N; Fritsche A; Artunc F
Cardiovasc Diabetol; 2019 Apr; 18(1):46. PubMed ID: 30953516
[TBL] [Abstract][Full Text] [Related]
37. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Ku EJ; Lee DH; Jeon HJ; Oh TK
Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
[TBL] [Abstract][Full Text] [Related]
38. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
[TBL] [Abstract][Full Text] [Related]
39. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
